J. Tol

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial

Géraldine Gebhart, Laetitia E. Lamberts, Zéna Wimana et al. · Annals of Oncology · 2015 · 348 citations · Full text

Medicine, Molecular Medicine, Oncology +17

KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients

Nikki Knijn, Leonie J. Mekenkamp, Marjolein Klomp et al. · British Journal of Cancer · 2011 · 289 citations · Full text

Medicine, Oncology, Pathology +16

A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity

J. Tol, Miriam Koopman, C. J. Rodenburg et al. · Annals of Oncology · 2008 · 215 citations

Medicine, Oncology, Pharmacology +17

Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents

J. Tol, Miriam Koopman, Michael Craig Miller et al. · Annals of Oncology · 2009 · 213 citations

Medicine, Oncology, Pharmacology +16

Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG)

C.J.A. Punt, J. Tol, C. J. Rodenburg et al. · Journal of Clinical Oncology · 2008 · 130 citations

Medicine, Oncology, Pharmacology +16